Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121192 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
A Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 776
- Enrollment target
- 20
- Study locations
NCT07121192: Active Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.
NCT07121192 is a Phase 2 study of Influenza, Human that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 776 participants, below the 16,180-participant average among 18 other Influenza, Human trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07121192, a Phase 2 study of Influenza, Human, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 776 participants
- Enrollment target
- 20
- Study locations
Study Summary
"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."
Conditions Studied
Interventions
- COMBINATION_PRODUCT Comparator 1
- COMBINATION_PRODUCT Comparator 2
- BIOLOGICAL Flu mRNA (Formulation A)
- BIOLOGICAL Flu mRNA (Formulation B)
- COMBINATION_PRODUCT Comparator 3
Study Locations (20)
California
- GSK Investigational Site - Fair Oaks
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - Walnut Creek
Florida
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Jupiter
- GSK Investigational Site - Miami
Texas
- GSK Investigational Site - Austin
- GSK Investigational Site - DeSoto
- GSK Investigational Site - Fort Worth
Alabama
- GSK Investigational Site - Anniston
Georgia
- GSK Investigational Site - Atlanta
Indiana
- GSK Investigational Site - Valparaiso
Kansas
- GSK Investigational Site - Lenexa
Massachusetts
- GSK Investigational Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 2 |
What the registry record for NCT07121192 still lists
NCT07121192 is an interventional study that assigns participants to a tested intervention. The registered 776 participants enrollment target is mid-sized for trials with a published cap, below the 16,180-participant average among 18 other Influenza, Human trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions - of which Comparator 1 is the first listed.
NCT07121192 names 20 study sites across 13 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07121192 about?
NCT07121192 is a clinical study titled "A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older". "The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."
What is the current status of trial NCT07121192?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 776 participants. The study started on 2025-08-25. Estimated completion is 2026-05-15.
What conditions does trial NCT07121192 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT07121192?
The interventions under investigation include: Comparator 1 (COMBINATION_PRODUCT), Comparator 2 (COMBINATION_PRODUCT), Flu mRNA (Formulation A) (BIOLOGICAL), Flu mRNA (Formulation B) (BIOLOGICAL), Comparator 3 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07121192?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07121192 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07121192's enrollment target sits among peer trials
776 8th of 18 higher than 11 of 18 other Influenza, Human trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza, Human trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
COMPLETED · Phase 2
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
-
Flu Infection at UPHS
RECRUITING
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT03460769 · 775 participants
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI